Effectiveness of Antipsychotics Dips for Women After Age 45 Years
MONDAY, Oct. 24, 2022 (HealthDay News) -- Antipsychotic effectiveness declines in women after the age of 45 years, according to a study published online Oct. 5 in Schizophrenia Bulletin.
Iris E. Sommer, M.D., Ph.D., from the University Medical Center Groningen in the Netherlands, and colleagues used Finnish nationwide registers (61,889 individuals) to identify persons with schizophrenia/schizoaffective disorder and stratify by sex and age. Hospitalizations for psychosis were assessed by age group from 1996 to 2017.
The researchers found that starting at age 45 to 50 years, women were consistently more often hospitalized for psychosis than their male peers. For antipsychotic monotherapy >0.6 defined daily doses (DDDs)/day, women aged 45 years and older had a significantly higher risk for psychosis hospitalization than women younger than 45 years and compared with men at >1.1 DDDs/day. This sex- and age-dependent decrease in effectiveness was present for clozapine doses >0.6 DDDs/day, olanzapine doses >1.4 DDDs/day, and for specific doses of quetiapine (0.9 to 1.1 DDDs/day) and risperidone (0.6 to 0.9 DDDs/day).
"Starting in mid-forties, older women with schizophrenia-spectrum disorders should be regarded as a vulnerable group that deserve special attention," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
Related Posts
Mujeres otorgan mejor calificación a la reconstrucción mamaria con tejido autólogo
MIÉRCOLES, 4 de octubre de 2023 (HealthDay News) - Las mujeres que se someten a...
Los pesticidas en el trabajo podrían aumentar las probabilidades de EPOC, una enfermedad pulmonar
LUNES, 31 de enero de 2022 (HealthDay News) -- La exposición en el lugar de...
9-Year-Old Becomes 10th Casualty of Astroworld’s Crowd Surge
MONDAY, Nov. 15, 2021 (HealthDay News) -- A young boy who was injured at the...